Physician profile
Michael Choi
NPI 1871912279
$3,438.87
in general payments reported to CMS, 2019-2025
22 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $154 · 2021: $426 · 2022: $450 · 2023: $391 · 2024: $811 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,217 · Entertainment: $14.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.27 |
| Entertainment | $14.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $673.26 | 2019-2025 | Rocklatan, Clareon, Rhopressa |
| Sight Sciences, INC. | $580.73 | 2021-2024 | Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $465.20 | 2020-2025 | |
| Bausch & Lomb Americas INC. | $349.40 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Teva Pharmaceuticals USA, INC. | $245.51 | 2023-2025 | Uzedy, Austedo Xr |
| Oyster Point Pharma, INC. | $186.61 | 2022-2025 | Tyrvaya, Ryzumvi |
| Amgen INC. | $171.63 | 2024-2025 | Tepezza |
| Allergan, INC. | $166.35 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $133.74 | 2021-2022 | |
| Horizon Therapeutics Plc | $117.78 | 2022-2023 | Tepezza |
| Abbvie INC. | $91.83 | 2022-2025 | Durysta |
| Tarsus Pharmaceuticals, INC. | $36.43 | 2025 | Xdemvy |
| Dompe US, INC. | $34.53 | 2024 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.62 | 2021 | |
| Aerie Pharmaceuticals, INC. | $24.50 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $23.54 | 2025 | Iyuzeh |
| Biotissue Holdings INC. | $23.40 | 2024 | |
| Rxsight INC | $22.68 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Eyepoint US, INC. | $18.39 | 2019 | |
| Ocular Therapeutix, INC. | $15.42 | 2023 | Dextenza |
| Optos, INC. | $14.70 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Mallinckrodt Hospital Products INC. | $14.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.